NICE
OHE at iHEA Boston 2017: Meet the Team
5 July 2017
The 2017 iHEA congress will be held in Boston, 7th-11th July 2017. Members of the OHE team will be attending and participating in the conference, and…
OHE at ISPOR Boston 2017: Presentations and Posters
4 July 2017
A selection of the posters and presentations delivered by OHE at the ISPOR 22nd Annual International Meeting in Boston, May 2017, are available below. Adrian Towse…
OHE at HTAi 2017: Meet the Team
13 June 2017
The HTAi Annual Meeting 2017 will be held in Rome, Italy, 17-21st June 2017. The theme of the meeting is Towards an HTA Ecosystem: From Local…
Multi-criteria Decision Analysis (MCDA) to Support Healthcare Decisions: Opportunities, Challenges and Unresolved Questions
18 May 2017
Just published is a new book entitled “Multi-criteria Decision Analysis (MCDA) to Support Healthcare Decisions”. It features a chapter by OHE’s Martina Garau and Professor Nancy…
Is There Societal Support for an End of Life Premium?
8 May 2017
OHE’s Koonal Shah gave a presentation on the evidence of societal support for an end of life premium at the Pharmaccess Leaders Forum in Milan on…
Do People of Different Ages Value Health Differently?
18 April 2017
A new OHE Research Paper entitled “Age and Utilities: Issues for HTA” is available to download.
How Important are the Differences Between the EQ-5D-5L and EQ-5D-3L Value Sets?
24 March 2017
There are three EQ-5D value sets available for use in cost effectiveness analysis in the UK and/or England: – the UK EQ-5D-3L value set (often called…
Important Variations in Access to Orphan Drugs in France, Italy, Germany, Spain and the UK
14 March 2017
A new OHE report compares the availability and access of orphan medicinal products (OMPs) in the UK, France, Germany, Italy and Spain.
New OHE Consulting Report: Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
16 February 2017
Just published is a new OHE Consulting Report entitled: Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit…